,
Avila-Tomas, J. F.
Olano-Espinosa, E.
Minué-Lorenzo, C.
Martinez-Suberbiola, F. J.
Matilla-Pardo, B.
Serrano-Serrano, M. E.
Escortell-Mayor, E.
Funding for this research was provided by:
Instituto de Salud Carlos III (PI17/01942)
Article History
Received: 17 October 2019
Accepted: 8 November 2019
First Online: 3 December 2019
Ethics approval and consent to participates
: This clinical trial was approved by the Clinical Research Ethics Committees of the Community of Madrid (December 13th, 2017) and the University Hospital 12 de Octubre (Madrid, January 30th, 2018). Both committees are comprised of qualified medical and scientific staff. The rights and wellbeing of patients will be respected at all times. All patients will be properly informed both verbally and in writing about the nature, objectives, risks, and potential benefits of the trial. Informed consent, written, signed, and dated, will be required from each subject.The trial will comply with the Spanish law on human experimentation and will respect all the ethical principles of autonomy, justice, goodness of intention, and absence of intentionality in accordance with the good clinical practice standards of the Declaration of Helsinki (Seoul, 2008) and the Convenio de Oviedo (Oviedo, 1997).A personal identification number (PIN) will be automatically generated that will be the unique identifier of the patient, hence dissociating their clinical and personal data. This PIN, together with a password, will also allow subjects in the intervention group to access the chat-bot.The chat-bot will not be used to collect any data allowing for identifying the user.
: Not applicable.
: The authors declare that they have no competing interests.